MedPath

Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-
Clinical Trials
Related News

Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer

Phase 2
Completed
Conditions
Squamous Cell Carcinoma
Interventions
Radiation: Radiotherapy
Drug: Paclitaxel
Drug: Carboplatin
First Posted Date
2005-09-15
Last Posted Date
2023-05-16
Lead Sponsor
Susanne Arnold
Target Recruit Count
40
Registration Number
NCT00176254

Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer

Phase 1
Terminated
Conditions
Head and Neck Cancer
Interventions
Drug: gemcitabine
Drug: paclitaxel
Radiation: radiation
First Posted Date
2005-09-15
Last Posted Date
2015-06-08
Lead Sponsor
Susanne Arnold
Target Recruit Count
7
Registration Number
NCT00176241
Locations
🇺🇸

University of Kentucky, Lexington, Kentucky, United States

Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer

Phase 1
Completed
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: Paclitaxel
Procedure: Radiation Therapy
First Posted Date
2005-09-15
Last Posted Date
2015-08-21
Lead Sponsor
University of Rochester
Target Recruit Count
41
Registration Number
NCT00178256
Locations
🇺🇸

University of Rochester, Dept. Radiation Oncology, Rochester, New York, United States

Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer

Phase 2
Completed
Conditions
Squamous Cell Carcinoma
Interventions
Radiation: Radiotherapy
Drug: Paclitaxel
Drug: Carboplatin
First Posted Date
2005-09-15
Last Posted Date
2023-06-01
Lead Sponsor
Susanne Arnold
Target Recruit Count
26
Registration Number
NCT00176267

Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer

Phase 2
Completed
Conditions
Ovarian Cancer
Interventions
Drug: Paclitaxel
Drug: Carboplatin
First Posted Date
2005-09-15
Last Posted Date
2016-03-25
Lead Sponsor
North Eastern German Society of Gynaecological Oncology
Target Recruit Count
129
Registration Number
NCT00170664
Locations
🇩🇪

Charité Campus Virchow-Klinikum, Berlin, Germany

Taxol Carboplatin and Erythropoetin

Phase 2
Completed
Conditions
Ovarian Cancer
Interventions
Drug: Paclitaxel
First Posted Date
2005-09-12
Last Posted Date
2017-02-06
Lead Sponsor
North Eastern German Society of Gynaecological Oncology
Target Recruit Count
105
Registration Number
NCT00158379

Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling

Phase 2
Terminated
Conditions
Advanced Non-Small Cell Lung Cancer
First Posted Date
2005-09-12
Last Posted Date
2008-07-30
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
1
Registration Number
NCT00161278
Locations
🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

Phase 2
Completed
Conditions
Carcinoma
Non-Squamous Non-Small-Cell Lung Cancer
Interventions
Drug: Carboplatin
Drug: Paclitaxel
Drug: CDP791 10mg/kg
Drug: CDP791 20mg/kg
First Posted Date
2005-09-09
Last Posted Date
2022-04-12
Lead Sponsor
UCB Pharma
Target Recruit Count
165
Registration Number
NCT00152477

Preoperative Herceptin and Navelbine for Breast Cancer

Phase 2
Completed
Conditions
Stage III Breast Cancer
Breast Cancer
Stage II Breast Cancer
Interventions
Drug: Herceptin
Drug: Navelbine
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel
First Posted Date
2005-09-08
Last Posted Date
2019-01-15
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
49
Registration Number
NCT00148681
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Center, Boston, Massachusetts, United States

Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: Estramustine
Drug: Etoposide
Drug: Paclitaxel
First Posted Date
2005-09-08
Last Posted Date
2015-01-21
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
28
Registration Number
NCT00151060
Locations
🇺🇸

The University of Michigan Comprehensive Cancer, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy